BiomX Inc.
PHGE-WT
New York Stock Exchange Arca0.01
USD
+0.01
- -
BiomX Inc.
PHGE-WT
(New York Stock Exchange Arca)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BiomX Inc (NYSE American: PHGE; PHGE-WT), a clinical-stage biopharmaceutical company, develops natural and engineered phage therapies that target and eradicate specific harmful bacteria associated with chronic diseases; its core pipeline includes BX004, a fixed multi-phage cocktail in Phase 2b trials for chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, BX211, a phage therapy that achieved positive Phase 2 topline results in March 2025 showing over 40% wound size reduction versus placebo in diabetic foot osteomyelitis patients with Staphylococcus aureus infections, and BX011, a next-generation fixed multi-phage cocktail derived from BX211 phages advancing toward a Phase 2a study for S. aureus-associated diabetic foot infections following positive FDA feedback in November 2025 on its clinical development pathway toward a potential Biologics License Application. The company leverages its proprietary platforms, including the BacteriOphage Lead to Treatment (BOLT) system for rapid phage development and XMarker for microbiome-based target identification, to create customized cocktails active against antibiotic-resistant strains and biofilms. BiomX operates in the biotechnology sector focusing on microbiome therapeutics for unmet needs in respiratory and wound infections, serving patients with cystic fibrosis, diabetes-related complications, and related conditions primarily in the United States and Israel. Founded in 2015 and headquartered in Ness Ziona, Israel, with facilities in Gaithersburg, Maryland, USA, the company completed a transformative merger with Adaptive Phage Therapeutics in March 2024 supported by $50 million in concurrent financing from investors including Deerfield Management, OrbiMed, and the Cystic Fibrosis Foundation to advance its Phase 2 assets; recent developments encompass initiation of BX004 Phase 2b patient dosing in July 2025 with topline data expected in Q1 2026, a temporary FDA clinical hold resolution underway for U.S. trials, positive real-world evidence analysis for Pseudomonas reduction in cystic fibrosis, a 1-for-19 reverse stock split in November 2025, and ongoing discussions with the U.S. Defense Health Agency for phage applications in infections.